Andrea Havasi, M.D. is an Assistant Professor of Medicine at Boston University. She is board certified in Internal Medicine and Nephrology. As a recipient of the National Kidney Foundation Research Fellow Award, she undertook research training at BMC investigating the cytoprotective mechanisms of heat shock proteins in ischemic renal cell injury and apoptosis. She joined the Renal Section Faculty in 2008, and continues basic and translational research in the area of renal cell injury and proteinuric kidney diseases using cell culture and animal models. She is the recipient of the American Heart Association Scientist Development Grant and NIH K08 award. She also has a special clinical and research interest in onco-nephrology and amyloidosis, and is a faculty in BU’s Amyloidosis Center. Dr. Havasi is a Co-Director of BU’s Mitochondria Affinity Research Collaborative, and Director of Nephrology Fellowship Program’s Onco-nephrology / Amyloidosis Pathway. Her clinical roles include attending time on the consult and dialysis/transplant services and weekly outpatient clinics (amyloidosis, chronic kidney disease, hemodialysis and peritoneal dialysis clinics).
Current research interest:
1. Amyloid renal disease
Mechanism of amyloid fibril formation and deposition in the kidney.
2. Proteinuria and renal fibrosis
Mechanisms of proteinuria induced tubular damage, interstitial fibrosis and inflammation in progressive kidney diseases. Proteinuria is associated with progressive chronic kidney disease. It is well known that exposure of proximal tubular epithelial cells to large amounts of albumin leads to the development of tubular atrophy and fibrosis. However, the possible pathogenic role of albumin in this process has not been fully elucidated. Development of new therapeutic tools to prevent or slow the progression of proteinuric chronic kidney disease requires clear understanding of the effect of proteinuria on tubular cell function.
- Member, Amyloidosis Center, Boston University
- Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
- Semmelweis University, MD
- Published on 7/31/2020
Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V. Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis. Leukemia. 2020 Jul 31. PMID: 32737434.
- Published on 7/20/2020
Wang Z, Belghasem M, Salih E, Henderson J, Igwebuike C, Havasi A, Borkan SC. T95 nucleophosmin phosphorylation as a novel mediator and marker of regulated cell death in acute kidney injury. Am J Physiol Renal Physiol. 2020 Sep 01; 319(3):F552-F561. PMID: 32686519.
- Published on 4/3/2020
Igwebuike C, Yaglom J, Huiting L, Feng H, Campbell JD, Wang Z, Havasi A, Pimentel D, Sherman MY, Borkan SC. Cross organelle stress response disruption promotes gentamicin-induced proteotoxicity. Cell Death Dis. 2020 Apr 03; 11(4):217. PMID: 32245975.
- Published on 3/9/2020
Angel-Korman A, Stern L, Angel Y, Sarosiek S, Menn-Josephy H, Francis J, Ghai S, Sloan JM, Sanchorawala V, Havasi A. The Role of Kidney Transplantation in Monoclonal Ig Deposition Disease. Kidney Int Rep. 2020 Apr; 5(4):485-493. PMID: 32274452.
- Published on 2/11/2020
Angel-Korman A, Havasi A. Kidney Transplantation in Systemic Amyloidosis. Transplantation. 2020 Feb 11. PMID: 32053574.
- Published on 10/9/2019
Angel-Korman A, Jaberi A, Sanchorawala V, Havasi A. The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis. Amyloid. 2020 Mar; 27(1):17-24. PMID: 31595786.
- Published on 1/1/2019
Wang Z, Salih E, Igwebuike C, Mulhern R, Bonegio RG, Havasi A, Borkan SC. Nucleophosmin Phosphorylation as a Diagnostic and Therapeutic Target for Ischemic AKI. J Am Soc Nephrol. 2019 01; 30(1):50-62. PMID: 30573638.
- Published on 12/21/2018
Angel-Korman A, Stern L, Sarosiek S, Sloan JM, Doros G, Sanchorawala V, Havasi A. Long-term outcome of kidney transplantation in AL amyloidosis. Kidney Int. 2019 02; 95(2):405-411. PMID: 30580886.
- Published on 2/24/2018
Havasi A, Doros G, Sanchorawala V. Predictive value of the new renal response criteria in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2018 05; 93(5):E129-E132. PMID: 29430701.
- Published on 9/12/2017
Wang Z, Gall JM, Bonegio R, Havasi A, Illanes K, Schwartz JH, Borkan SC. Correction for Wang et al., "Nucleophosmin, a Critical Bax Cofactor in Ischemia-Induced Cell Death". Mol Cell Biol. 2017 10 01; 37(19). PMID: 28899998.
View 26 more publications: View full profile at BUMC